Director/PDMR Share Dealings

    June 30, 2015 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") announces
    that Ordinary Shares ("Shares") and American Depositary Shares ("ADSs") of the
    Company, as set out below, have been acquired today for the Non-Executive
    Directors, being the part of their total fees that are paid in shares for the
    period of service from April 1 to June 30, 2015.

                       Type of Security (1)    Number of Shares/ADSs  
                                                                      
    Dominic Blakemore  Shares                              114        
                                                                      
    William Burns      Shares                              126        
                                                                      
    Dr. Steven Gillis  ADSs                                 40        
                                                                      
    Dr. David Ginsburg ADSs                                 36        
                                                                      
    David Kappler      Shares                              126        
                                                                      
    Susan Kilsby       ADSs                                133        
                                                                      
    Anne Minto         Shares                              128        

    (1)                One ADS is equal to three Shares

    The Shares and ADSs were acquired on the London Stock Exchange and NASDAQ
    respectively at £51.05 per Share and $241.4578 per ADS.

    This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a)
    of the Disclosure and Transparency Rules.

    Tony Guthrie
    Deputy Company Secretary

    For further information please contact:

    Investor Relations                                                           
                                                                                 
    Sarah Elton-Farr                      seltonfarr@shire.com +44 1256 894157   

    NOTES TO EDITORS

    Shire enables people with life-altering conditions to lead better lives.

    Our strategy is to focus on developing and marketing innovative specialty
    medicines to meet significant unmet patient needs.

    We focus on providing treatments in Rare Diseases, Neuroscience,
    Gastrointestinal and Internal Medicine and we are developing treatments for
    symptomatic conditions treated by specialist physicians in other targeted
    therapeutic areas, such as Ophthalmics.

    http://www.shire.com/